Cantor Initiates Heron Therapeutics With Buy Rating, $41 Price Target

By: via Benzinga
Cantor Fitzgerald’s Chiara Russo mentioned that with Heron Therapeutics Inc (NASDAQ: HRTX)'s lead product, Sustol, coming up for ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.